PIK3CA and carcinoma: With regard to the clinical stage, the prevalence was significantly higher in stage IV carcinomas as compared to stage I–III carcinomas (CCNL1: P<0.001; SNO: P=0.05; PIK3CA: P=0.009; TP73L: P=0.03).